During the last three months, 25 analysts shared their evaluations of Exelixis EXEL, revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 8 | 9 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 3 | 1 | 4 | 0 | 0 |
| 2M Ago | 3 | 6 | 3 | 0 | 0 |
| 3M Ago | 2 | 0 | 2 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.32, with a high estimate of $45.00 and a low estimate of $29.00. This current average reflects an increase of 7.88% from the previous average price target of $35.52.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Exelixis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gregory Renza | RBC Capital | Raises | Outperform | $40.00 | $38.00 |
| Derek Archila | Wells Fargo | Maintains | Equal-Weight | $36.00 | $36.00 |
| Peter Lawson | Barclays | Raises | Equal-Weight | $29.00 | $25.00 |
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $40.00 | $40.00 |
| David Lebowitz | Citigroup | Raises | Buy | $45.00 | $38.00 |
| Michael Schmidt | Guggenheim | Maintains | Buy | $42.00 | $42.00 |
| Sudan Loganathan | Stephens & Co. | Maintains | Equal-Weight | $29.00 | $29.00 |
| Stephen Willey | Stifel | Raises | Hold | $36.00 | $30.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $38.00 | $37.00 |
| Ashwani Verma | UBS | Raises | Neutral | $34.00 | $30.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $41.00 | $41.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $43.00 | $42.00 |
| Sudan Loganathan | Stephens & Co. | Maintains | Equal-Weight | $29.00 | $29.00 |
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $40.00 | $40.00 |
| Jefferson Harralson | Morgan Stanley | Raises | Overweight | $40.00 | $30.00 |
| Jay Olson | Oppenheimer | Lowers | Perform | $33.00 | $41.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $41.00 | $41.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $41.00 | $38.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $42.00 | $38.00 |
| Silvan Tuerkcan | JMP Securities | Raises | Market Outperform | $41.00 | $34.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $37.00 | $36.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $40.00 | $29.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $42.00 | $33.00 |
| Etzer Darout | BMO Capital | Raises | Market Perform | $40.00 | $36.00 |
| Jason Gerberry | B of A Securities | Raises | Neutral | $39.00 | $35.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Exelixis compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Exelixis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Exelixis's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Exelixis analyst ratings.
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Financial Insights: Exelixis
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Exelixis showcased positive performance, achieving a revenue growth rate of 18.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Exelixis's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 24.68%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's ROA stands out, surpassing industry averages. With an impressive ROA of 4.73%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Exelixis adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
